Greenwich LifeSciences, Inc. (GLSI) Form 10-Q — Jun 3, 2026
Greenwich LifeSciences reported a net loss of $5.7 million for the first quarter of 2026, more than double the $2.7 million loss recorded in the same period last year, driven by a 129% increase in R&D expenses to $5.2 million as it expands its Phase III Flamingo-01 trial. The company raised approximately $9.3 million in gross proceeds through At-The-Market (ATM) equity offerings in Q1 2026 at an average price of $25.33 per share, and an additional $320,000 in April 2026, bringing its cash position to $10.5 million as of March 31, 2026.
Key figures
- Revenue
- 0
- Total Debt
- 0
- Total Assets
- 10505435
- Cash Position
- 10505435
- Shares Outstanding
- 14665993
- Accounts payable
- 4288183
- Ga expenses q1 2026
- 518190
- Rd expenses q1 2026
- 5207564
- Atm avg price q1 2026
- 25.33
- Atm shares sold q1 2026
- 367547
- Atm avg price april 2026
- 26.22
- Atm net proceeds q1 2026
- 9029912
- Atm shares sold april 2026
- 12215
- Atm net proceeds april 2026
- 310664
- Stock based compensation q1 2026
- 1544214
Price after filing
Close on the filing date to close N calendar days later (from $24.29). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.